Dec 15, 2023

New Drug Application of Mabwell's 8MW0511 for Injection Accepted by NMPA

➞

Dec 14, 2023

Mabwell's Mailishu and Junmaikang Continuing to be Included in the National Medical Insurance Will Benefit More Patients

➞

Dec 07, 2023

Mabwell Announces the CDE Approval of Novel Nectin-4 Targeting ADC for Phase III Clinical Trial

➞

Nov 28, 2023

Mabwell Partners with Innobic (Asia) Co., Ltd. to Market its products in Thailand

➞

Nov 16, 2023

Mabwell Announces the Appointment of Dr. Hai Wu as the President of R&D

➞

Oct 30, 2023

Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Argentina Market

➞

Oct 25, 2023

Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell’s 9MW2821 at 2023 ESMO

➞

Oct 23, 2023

Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs

➞

Sep 27, 2023

Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor

➞

Sep 26, 2023

Mabwell Partners with Legrand to Market Denosumab Biosimilars in Colombia and Ecuador

➞